MISSOURI VALLEY CANCER CONSORTIUM

密苏里河谷癌症联盟

• 批准号: 2105968
• 负责人: JAMES A MAILLIARD
• 金额: $ 25.52万
• 依托单位: CANCER ALLIANCE OF NEBRASKA
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 1997-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2105968
• 关键词: breast neoplasms; cancer prevention; clinical trials; community health services; cooperative study; data collection methodology /evaluation; human subject; neoplasm /cancer education; neoplasm /cancer therapy; patient /disease registry; prostate neoplasms; regional medical planning

The proposed Missouri Valley Cancer Consortium (MVCC) will be a multi- component community-based cancer research effort based in Omaha and Lincoln, Nebraska. The catchment area includes western Iowa and east- central Nebraska. The 1990 population was about 1.2 million. The Omaha affiliate has been commended as one of the largest accruers of patients in the North Central Cancer Treatment Group. The--four main components of the MVCC would be: Bergan Mercy Medical Center, Langdon & Block, P.C., Lincoln Cancer Center, and the Creighton Cancer Center. These institutions have had an established research program with the North Central Cancer Treatment Group (NCCTG) since 1983. Numerous investigators (33) participate and are responsible for over 2,990 new cancer patients annually. Over the past 10 years, these investigators have entered 1,628 patients on NCCTG protocols alone with recent average of 285 patients annually. In 1992, these investigators entered 191 and 94 patients on NCI-approved cancer treatment and control trials, respectively. The proposed principal and associate principal investigators of the MVCC are currently directing the conduct of the Breast Cancer Prevention Trial (97 accrued to date) and the Prostate Cancer Prevention Trial (initiation 10/93) for the state of Nebraska. Current research base affiliations with NCCTG, ECOG, and NSABP would continue and enable the future support of this high level of accrual as a NCI-funded CCOP.

拟议的密苏里河谷癌症联盟 (MVCC) 将是一个多方合作组织 组成部分基于社区的癌症研究工作，总部设在奥马哈和 内布拉斯加州林肯。 流域范围包括爱荷华州西部和东部 内布拉斯加州中部。 1990年人口约为120万。 奥马哈附属公司被誉为最大的累积者之一 北中央癌症治疗组的患者。 ——四个主要 MVCC 的组成部分包括：Bergan Mercy 医疗中心、Langdon & Block，P.C.、林肯癌症中心和克赖顿癌症中心。 这些机构已与北方建立了研究计划 中央癌症治疗组 (NCCTG) 自 1983 年起成立。众多研究人员 (33) 参与并负责超过 2,990 名新癌症患者 每年。 过去 10 年里，这些调查人员已进入 1,628 仅接受 NCCTG 方案的患者，最近平均有 285 名患者 每年。 1992 年，这些研究人员对 191 名和 94 名患者进行了研究 NCI 分别批准了癌症治疗和对照试验。 这 拟议的 MVCC 首席研究员和副首席研究员是 目前指导乳腺癌预防试验的进行（97 迄今为止累计）和前列腺癌预防试验（启动 10/93）内布拉斯加州。 目前的研究基地隶属关系 NCCTG、ECOG 和 NSABP 将继续提供未来支持 作为 NCI 资助的 CCOP，应计金额达到如此高的水平。